ArticleActa ophthalmologica2025
Aqueous humour concentrations of HB-EGF, EGF and VEGF-A and axial length in humans.
Article in Acta ophthalmologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Myopia as a Global Public Health Challenge a Narrative Review.Life (Basel, Switzerland) · 2026Review
- Aqueous humour concentrations of HB-EGF, EGF and VEGF-A and axial length in humans.Acta ophthalmologica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeTo investigate relationships between the intraocular concentrations of heparin-binding epidermal growth factor (HB-EGF), epidermal growth factor (EGF) and vascular endothelial growth factor A (VEGF-A) in dependence on axial length in humans.
designClinical interventional cohort study.
participantsPatients with cataract who underwent routine cataract surgery. Inclusion criterion was the absence of any retinal or optic nerve disease except for myopic macular degeneration (MMD) without myopic choroidal neovascularization.
methodsUsing a Luminex system, we measured the concentrations of HB-EGF, EGF and VEGF-A in aqueous humour samples taken from patients during cataract surgery.
main outcome measuresIntracameral concentration of EGF, HB-EGF and VEGF; Axial length.
resultsThe study included 68 patients (age: 61.1 ± 11 years; range: 44-85 years) with a mean axial length of 27.11 ± 3.11 mm (range: 22.09-35.64 mm). The HB-EGF concentration (mean: 3.17 ± 0.99 pg/mL) increased with longer axial length (β = 0.43; p < 0.001) and was not associated with age (p = 0.10) and intracameral EGF concentration (p = 0.22). The EGF concentration (mean: 0.22 ± 0.12 pg/mL) increased with longer axial length (β = 0.35; p = 0.004) and higher prevalence of advanced MMD (β = 0.35; p = 0.008) and was not associated with age (p = 0.28) and intracameral VEGF-A concentration (p = 0.09). The VEGF-A concentration (mean: 118 ± 150 pg/mL) decreased with longer axial length (β = -0.54; p < 0.001), higher intracameral concentration of HB-EGF (β = -0.26; p = 0.03) and lower MMD prevalence (β = -0.31; p = 0.02) and was not associated with age (p = 0.47) and intracameral EGF concentration (p = 0.09).
conclusionsWith the concentrations of HB-EGF and EGF increasing with longer axial length, the study supports a potential role of the EGFR signalling pathway activation in human axial myopia. The inverse relationship between VEGF-A concentration and longer axial length agrees with a protective effect of axial myopia against diabetic retinopathy and age-related macular degeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.